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Sepsis is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection [1].
In the past decades many clinical trials tested immune
modulatory compounds designed to restore homeostasis
in patients with sepsis [2, 3]. In spite of these efforts,
costing hundreds of millions of dollars, not a single new
drug was integrated into clinical practice. Thus, it is ob-
vious that the clinical and scientific communities need
to reconsider the therapeutic approach to sepsis. Novel
strategies to treat sepsis face serious challenges in their
path to the patient in the intensive care unit (ICU).
The first question one might ask when confronted
with the many negative sepsis trials is whether our current
understanding of the pathophysiology of sepsis is correct.
The traditional concept of sepsis as a syndrome caused by
uncontrolled injurious inflammation has been replaced by
the current model of a multifaceted host response, entail-
ing not only abundant and sustained inflammation, but
also lengthy immune suppression [4, 5]. It is now widely
acknowledged that acute preclinical sepsis models do not
adequately capture the prolonged course in patients with
sepsis, in whom the majority develop organ dysfunction
over the course of days with deaths occurring mostly more
than 1 week after ICU admission. Preclinical research on
novel therapeutic interventions should better integrate
current knowledge of the course and consequences of
sepsis, incorporating aged animals with comorbidity
and supportive care, including resuscitation and anti-
biotic therapy, in different models relevant for sepsis.
A second challenge results from the heterogeneity of
sepsis and the patients who are affected. Patients with
sepsis are quite heterogeneous, not only with respect to
the source of infection and causative pathogen, but also
with regard to age, genetic composition, comorbidities,
chronic medication, and life style. As a consequence, pa-
tients with sepsis have a wide variability in their risk of
death and in the absolute benefit that they can derive
from a given therapy. Considering the complexity of the
host response to sepsis, it is difficult to imagine that a
drug targeting one host mediator will provide benefit to
all sepsis patients.
What can be done to discover novel therapeutic targets
and to improve trial design for testing new interventions?
Adequate identification of drug targets should make use
of extensive preclinical research including both cellular
assays and a combination of animal models relevant for
sepsis. Importantly, the possible involvement of pathways
implicated in the outcome of experimental sepsis should
be verified in patients with sepsis by detailed measure-
ments over time. This research can also be used to de-
velop assays for sets of biomarkers that provide insight
into the activity of the targeted pathway; such assays can
then be used for inclusion of patients and to monitor the
effect of the intervention. This would address two serious
problems associated with sepsis trials performed in the
last decades. First, a biomarker-guided inclusion of pa-
tients is more likely to identify patients that might benefit
from a targeted therapy than the traditional inclusion of
patients based on clinical criteria. Second, such an ap-
proach likely results in more adequate dosing of novel
drugs, since this would be guided by measurement of
specific biological effects rather than by animal data
and relatively limited pharmacokinetic studies in
humans. Systems biology is expected to be valuable in
identifying sets of biomarkers and their use in what has
been called “personalized medicine”. In this respect, a
very recent manuscript describing two distinct host re-
sponse types in patients with severe community-acquired
pneumonia, based on analyses of the blood leukocyte
transcriptome, is of major interest; one host response type
was associated with a clear immune suppressive pheno-
type and increased mortality [6]. The authors reported a
set of seven genes that adequately discriminated the two
response types; these genes could be easily incorporated
in a polymerase chain-based bedside test to be used for
the identification of patients who might benefit (or not)
from immune stimulatory therapy. Evidence that the ef-
ficacy of a drug can be determined by the type of host
response was provided by a re-analysis of the pivotal
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trial with recombinant human interleukin-1 receptor
antagonist in patients with sepsis, showing that—while
the intervention overall had no effect—it strongly im-
proved survival in the subgroup of patients with signs
of a macrophage activation syndrome [7].
Another point of attention comes from the question
how to measure the success of a novel therapeutic. Since
the case fatality rate of sepsis has decreased [8, 9], the
long-term morbidity of sepsis has received increasing at-
tention [10]. End points beyond the traditional 28-day
mortality can capture late physical and cognitive seque-
lae, and could alter the focus for drug development,
moving away from attempts to modify the early course
of the host response and instead seeking to support fas-
ter and more complete recovery.
Evidence is emerging that non-infectious critical illness
can be associated with similar disturbances in host-
response pathways as observed in sepsis, especially after
a prolonged stay on the ICU [11]. Some critically ill patients
without infection might benefit from similar immune mod-
ulatory therapies as patients with sepsis, yet they have been
systemically excluded from sepsis trials. From a theoretical
perspective, it is worthy to evaluate drugs targeting a
specific host-response pathway in critically ill patients
in whom that pathway is disturbed irrespective of the
presence of infection as a triggering event.
It is time to implement new knowledge and technol-
ogy in the clinical evaluation of new sepsis treatments.
The challenge for the coming years will be to translate
the rapidly increasing understanding of the molecular
pathophysiology of sepsis into new drugs to be tested in
only those patients with sepsis (or non-infectious critical
illness) in whom the targeted pathway is derailed, making
use of rapid tests that can also monitor the drug effect in
time. The technology to manufacture bedside molecular
tests with very limited hands-on time is there, we now
need the intellectual contents with which these tests can
be filled. This approach, possibly combined with alterna-
tive trial designs and/or end points, may deliver the posi-
tive sepsis trials and the clinical implementation of new
sepsis strategies for which researchers and clinicians have
waited for a long time.
Abbreviation
ICU: intensive care unit.
Competing interests
The author declares that he has no competing interests.
Author’s contribution
TvdP drafted and approved the manuscript.
References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer
M, et al. The Third International Consensus Definitions for Sepsis and Septic
Shock (Sepsis-3). JAMA. 2016;315(8):801–10.
2. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;
20(4):195–203.
3. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al.
Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581–614.
4. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect
Dis. 2008;8(1):32–43.
5. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from
cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–74.
6. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills
TC, et al. Genomic landscape of the individual host response and
outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016.
doi:10.1016/S2213-2600(16)00046-1.
7. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et
al. Interleukin-1 receptor blockade is associated with reduced mortality in
sepsis patients with features of macrophage activation syndrome: reanalysis
of a prior phase III trial. Crit Care Med. 2016;44(2):275–81.
8. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the
incidence and mortality of severe sepsis in the United States. Crit Care
Med. 2013;41(5):1167–74.
9. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to
severe sepsis and septic shock among critically ill patients in Australia and
New Zealand, 2000–2012. JAMA. 2014;311(13):1308–16.
10. Yende S, Iwashyna TJ, Angus DC. Interplay between sepsis and chronic
health. Trends Mol Med. 2014;20(4):234–8.
11. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives.
Immunity. 2014;40(4):463–75.
van der Poll Critical Care  (2016) 20:106 Page 2 of 2
